Kyowa Hakko Kirin Co., Ltd. (4151) – Financial and Strategic SWOT Analysis Review

Kyowa Hakko Kirin Co., Ltd. (4151) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
64
Pharmaceuticals and Healthcare
Japan

Kyowa Hakko Kirin Co., Ltd. (4151) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko), formerly Kyowa Hakko Kogyo Co., Ltd., is a biotechnology company. It focuses on the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. Kyowa Hakko operates through two business segments, namely, Pharmaceuticals and Bio- chemicals. The company’s commercial products comprise for the therapeutic areas of Oncology, Nephrology and others include Gran, Nesp, Espo, Romiplate, Coniel, Regpara, Allelock/Patanol and Depakene/Topina among others. Its development pipeline consists of various protein, antibody and small molecule formulations such as Pegfilgrastim Injection, Cinacalcet Hydrochloride Oral, KW-6002 Istradefylline Oral, AMG531 Romiplostim Injection, Granisetron Patch and others. The products are developed for the treatment of diseases such as, neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company along with its subsidiaries operates in the US, Europe and Asia. Kyowa Hakko Kirin is headquartered in Tokyo, Japan.

Kyowa Hakko Kirin Co., Ltd. Key Recent Developments

Dec 16, 2013: Launch of Kyowa Hakko Kirin Thailand Website
Dec 02, 2013: Yokkaichi Plant Closed as Part of Production Facility Reorganization
Oct 25, 2013: Kyowa Hakko Kirin Third Quarter Operating Income up 10.9%
Oct 07, 2013: Announcement of Results from a Single Dose Phase 1 Study of a Human Monoclonal Anti-FGF23 Antibody (KRN23) in X-linked Hypophosphatemia in Adults
Sep 13, 2013: Launch of Kyowa Hakko Kirin Hong Kong Corporate Website

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Kyowa Hakko Kirin Co., Ltd. – Key Facts 6
Kyowa Hakko Kirin Co., Ltd. – Key Employees 7
Kyowa Hakko Kirin Co., Ltd. – Key Employee Biographies 9
Kyowa Hakko Kirin Co., Ltd. – Major Products and Services 10
Kyowa Hakko Kirin Co., Ltd. – Pharmaceutical Pipeline Products Data 13
Kyowa Hakko Kirin Co., Ltd., Pipeline Products by Therapy Area 13
Kyowa Hakko Kirin Co., Ltd., Pipeline Products by Development Phase 14
Kyowa Hakko Kirin Co., Ltd. – History 17
Kyowa Hakko Kirin Co., Ltd. – Company Statement 28
Kyowa Hakko Kirin Co., Ltd. – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Joint Venture 31
Section 2 – Company Analysis 32
Kyowa Hakko Kirin Co., Ltd. – Business Description 32
Business Description – Bio-Chemicals 32
Bio-Chemicals – Overview 32
Bio-Chemicals – Financials 33
Bio-Chemicals – Market View 33
Bio-Chemicals – Key Strategies 33
Bio-Chemicals – Technology 33
Business Description – Pharmaceuticals 33
Pharmaceuticals – Overview 33
Pharmaceuticals – Financials 33
Pharmaceuticals – Market View 34
Pharmaceuticals – Key Strategies 34
Pharmaceuticals – Technology 34
Kyowa Hakko Kirin Co., Ltd. – Corporate Strategy 35
Kyowa Hakko Kirin Co., Ltd. – SWOT Analysis 36
SWOT Analysis – Overview 36
Kyowa Hakko Kirin Co., Ltd. – Strengths 36
Strength – Expansion in Overseas Business 36
Strength – Integration of Archimedes 36
Strength – Extensive R&D Effort 36
Kyowa Hakko Kirin Co., Ltd. – Weaknesses 37
Weakness – Drug Price Revisions Affect Revenue 37
Weakness – Termination of Agreement with Amgen 37
Kyowa Hakko Kirin Co., Ltd. – Opportunities 38
Opportunity – Product Pipeline 38
Opportunity – Strategic Initiatives 38
Opportunity – Growing Opportunity in the Biosimilars Market 38
Kyowa Hakko Kirin Co., Ltd. – Threats 39
Threat – Competitive Pressures 39
Threat – Influx of Generics 39
Threat – Regulations of National Health Insurance in Japan 39
Kyowa Hakko Kirin Co., Ltd. – Key Competitors 40
Section 3 – Company Financial Ratios 41
Financial Ratios – Capital Market Ratios 41
Financial Ratios – Annual Ratios 42
Performance Chart 44
Financial Performance 44
Financial Ratios – Interim Ratios 45
Financial Ratios – Ratio Charts 46
Section 4 – Company’s Lifesciences Financial Deals and Alliances 47
Kyowa Hakko Kirin Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 47
Kyowa Hakko Kirin Co., Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 48
Kyowa Hakko Kirin Co., Ltd., Medical Equipment, Deals By Year, 2009 to YTD 2015 49
Kyowa Hakko Kirin Co., Ltd., Medical Equipment, Deals By Type, 2009 to YTD 2015 50
Kyowa Hakko Kirin Co., Ltd., Petrochemicals, Deals By Year, 2009 to YTD 2015 51
Kyowa Hakko Kirin Co., Ltd., Petrochemicals, Deals By Type, 2009 to YTD 2015 52
Kyowa Hakko Kirin Co., Ltd., Recent Deals Summary 53
Section 5 – Company’s Recent Developments 54
Oct 30, 2014: Kyowa Hakko Kirin Announces Completion of Construction for Drug Product Manufacturing Facility in the Takasaki Plant 54
Apr 08, 2014: Kyowa Hakko Kirin Announces Completion of Construction for the biopharmaceutical API manufacturing facility in the Takasaki Plant 55
Feb 28, 2014: Construction to Begin on New IK8 Research Building at Fuji Research Park 56
Jan 31, 2014: Kyowa Hakko Kirin to Consolidate and Reorganize Research and Development Divisions 57
Jan 31, 2014: Kyowa Hakko Kirin Announces Consolidated Financial Results For Fiscal Year Ended December 31, 2013 58
Section 6 – Appendix 60
Methodology 60
Ratio Definitions 60
About GlobalData 64
Contact Us 64
Disclaimer 64



List of Tables
Kyowa Hakko Kirin Co., Ltd., Key Facts 6
Kyowa Hakko Kirin Co., Ltd., Key Employees 7
Kyowa Hakko Kirin Co., Ltd., Key Employee Biographies 9
Kyowa Hakko Kirin Co., Ltd., Major Products and Services 10
Kyowa Hakko Kirin Co., Ltd., Number of Pipeline Products by Therapy Area 13
Kyowa Hakko Kirin Co., Ltd., Number of Pipeline Products by Development Stage 14
Kyowa Hakko Kirin Co., Ltd., Pipeline Products By Therapy Area and Development Phase 15
Kyowa Hakko Kirin Co., Ltd., History 17
Kyowa Hakko Kirin Co., Ltd., Other Locations 29
Kyowa Hakko Kirin Co., Ltd., Subsidiaries 30
Kyowa Hakko Kirin Co., Ltd., Joint Venture 31
Kyowa Hakko Kirin Co., Ltd., Key Competitors 40
Kyowa Hakko Kirin Co., Ltd., Ratios based on current share price 41
Kyowa Hakko Kirin Co., Ltd., Annual Ratios 42
Kyowa Hakko Kirin Co., Ltd., Interim Ratios 45
Kyowa Hakko Kirin Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 47
Kyowa Hakko Kirin Co., Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 48
Kyowa Hakko Kirin Co., Ltd., Medical Equipment, Deals By Year, 2009 to YTD 2015 49
Kyowa Hakko Kirin Co., Ltd., Medical Equipment, Deals By Type, 2009 to YTD 2015 50
Kyowa Hakko Kirin Co., Ltd., Petrochemicals, Deals By Year, 2009 to YTD 2015 51
Kyowa Hakko Kirin Co., Ltd., Petrochemicals, Deals By Type, 2009 to YTD 2015 52
Kyowa Hakko Kirin Co., Ltd., Recent Deals Summary 53
Currency Codes 60
Capital Market Ratios 60
Equity Ratios 61
Profitability Ratios 61
Cost Ratios 62
Liquidity Ratios 62
Leverage Ratios 63
Efficiency Ratios 63



List of Figures
Kyowa Hakko Kirin Co., Ltd., Pipeline Products by Therapy Area 13
Kyowa Hakko Kirin Co., Ltd., Pipeline Products by Development Phase 14
Kyowa Hakko Kirin Co., Ltd., Performance Chart (2010 – 2014) 44
Kyowa Hakko Kirin Co., Ltd., Ratio Charts 46
Kyowa Hakko Kirin Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 47
Kyowa Hakko Kirin Co., Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 48
Kyowa Hakko Kirin Co., Ltd., Medical Equipment, Deals By Year, 2009 to YTD 2015 49
Kyowa Hakko Kirin Co., Ltd., Medical Equipment, Deals by Type, 2009 to YTD 2015 50
Kyowa Hakko Kirin Co., Ltd., Petrochemicals, Deals By Year, 2009 to YTD 2015 51
Kyowa Hakko Kirin Co., Ltd., Petrochemicals, Deals by Type, 2009 to YTD 2015 52

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.